Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Butyl ether | HCID 8909 | — |
| Reactant | HCID 70798107 | HCID 70798107 | — |
| Reactant | HCID 178418573 | HCID 178418573 | — |
| Solvent | Tetrahydrofuran | HCID 8028 | — |
| Product | HCID 11573332 | HCID 11573332 | — |
Reaction Steps
Intermediate 13a (0.5 mmol) from above was dissolved in anhydrous tetrahydrofuran (1.0 mL) and treated with 2.0 eq methylmagnesium bromide in butyl ether (1.0 mL 1.0 M solution, 1.0 mmol). The vial was flushed with nitrogen and stirred at room temperature for 3 h. The reaction was diluted with ethyl acetate (5.0 mL), quenched with saturated aqueous ammonium chloride (1.0 mL) and stirred overnight at room temperature. The organic layer was separated, concentrated in vacuo, then dissolved in methanol:acetonitrile (3.0 mL, 1:1 v/v) and subjected to reverse-phase HPLC purification (5-50% CH3CN/0.08% TFA) to yield 4-(5-chloro-2-methoxyphenyl)-1-(1-methylcyclo-hexyl)piperidine (compound no. 300) as the TFA salt. LC/MS (RP-C18, 10-99% CH3CN/0.05% TFA gradient over 5 min) m/z 322.0 [M+H]+, retention time 2.39 min.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07880007B2 |
|---|
| Source dataset | uspto-grants-2011_02 |
|---|
| ORD ID | ord-ac826684f602492cb3d96cf78ec9f8d1 |
|---|
| Source note | uspto-grants-2011_02 |
|---|